? Neutralizing Antibodies: Research pathways in 2013 and beyond

Slides:

Advertisements

Similar presentations

1 Workshop on the immunological basis of vaccine efficacy Vaccine and Infectious Disease Institute December 14, 2009 Ira M. Longini, Jr. Center for Statistical.

Advertisements

AVAC Global Advocacy for HIV Prevention AIDS Vaccines: The basics May 2014.

Vaccines Robert Beatty MCB150. Passive vs Active Immunity  Passive immunization transfer of antibodies  Vaccines are active immunizations (mimic natural.

HIV-VACCINES. HIV - Vaccines  Vaccine development remains priority of AIDS research   Best hope for protection against HIV infection.

Overview of the Division of Viral Products

Informatics Support for Vaccine Projects Using and extending the UCSC bioinformatics infrastructure.

Principles of Immunology Immunizations 4/18/06 "Life is a long lesson in humility” James Barrie.

HIV Vaccine Research & Development

HIV Vaccine Clinical Trials: In Theory and on the Ground Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department of Medical Microbiology.

Novel strategies for prevention and treatment of HIV infection Prasit Faipenkhong Pairoaj Vonghathaipaisarn Rodjana Chunhabundit Zhang Jianjun.

UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES A Non-Replicating Ad5 Vaccine for the Treatment of HSV-2 Infection Wendy Peters, PhD | Associate Director.

RV 144: The Thai Phase III Trial and Development of a Globally-Effective, Multi-Clade HIV Vaccine HIV Vaccine: Quo Vadis AIDS July 2010 Dr. Merlin.

Lab of Immunoregulation Berkower Lab Weiss Lab -- Angelo Spadaccini -- Russell Vassell -- Yisheng Ni -- Yong He -- Yisheng Ni -- Yong He –Hong Chen --

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

1 Overview of the Laboratory of Hepatitis Viruses March 20, 2014 VRBPAC Discussion of the December 5, 2013 Site Visit for the Laboratory of Hepatitis Viruses.

Using Molecular Information to Investigate the Evolutionary Origin of the HIV Virus.

VACCINES: PRINCIPLES & PRACTICE. What is a vaccine? - an antigenic preparation used to produce active immunity to a disease, in order to prevent or ameliorate.

AIDS Vaccines: the basics CindraFeuer AVAC: Global Advocacy for HIV Prevention 20 April 2010 The HIV Research Catalyst Forum Baltimore, Maryland April.

© Arbovax Inc © Arbovax Inc Arbovax Arbovax ® Advanced technology for insect-borne virus vaccines Vaccines and Vaccination Valencia, Spain.

Gene Technology Chapter Basic Steps of Genetic Engineering Genetic Engineering – process of manipulating genes for practical purposes Genetic.

Immunogenicity of combined vaccines in infants Helena Käyhty, PhD National Public Health Institute Dept of Vaccines Helsinki, Finland.

Towards an antibody-based HIV vaccine

Chapter 31 review. 31.1: Pathogens and human illness Germs cause many diseases in humans. There are different types of pathogens. Pathogens can enter.

Immunotherapy By: Ray & Kelly Lewis David Duke Catherine Hanson Richard Hildreth.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Five: Immunology, Assay Standardization,

Primary Immunogenicity Endpoints for New Infant Pneumococcal Conjugate Vaccines Vaccines and Related Biological Products Advisory Committee Meeting Lucia.

Research on killer HIV antibodies provides promising new ideas for vaccine design New discoveries about the immune defenses of rare HIV patients who produce.

25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.

Immune system the system in the body that works to ward off infection and disease.

Making Vaccines. Effective Vaccines Have low levels of side effects or toxicity. Protect against exposure to natural, or wild forms of the pathogen. Should.

The Lymphatic System. Functions of Lymphatic System Drain fluid back into the bloodstream from tissues Filters lymph Filters the blood Fights infections.

1 Assessment of the Effectiveness of Small Pox Vaccines: Immunogenicity Assay Considerations Freyja Lynn Division of Bacterial, Parasitic and Allergenic.

CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

HIV Infection Chapter 30 Lesson One pg. 658 Global burden of HIV Over 25 million have died from AIDS leading cause of death in developing countries (WHO.

HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.

Viral vaccines .

Influence of Adjuvants on HIV Env Clade C Immunity

HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK

Moral Monday BW Should patients be given refunds when a vaccine doesn’t work?

Experimental Medicine Trials of Promising HIV Candidates

Appendix III: Scope of Service of CUHK Service Units

Scientific Challenges for the Development of an HIV Vaccine

Chapter 7-Vaccines Vaccination Current and future vaccines

The course of HIV infection

Immunology & Public Health

Viruses Virus: A biological particle composed of nucleic acid and protein pathogen: anything that causes sickness or disease.

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a.

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

From Bench to Clinical Applications: Money Talks

National High Magnetic Field Laboratory

Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

Discussion Outline Cells of the Immune System.

HIV Attachment and Entry: Pursuing a Challenging Target

Peter D. Kwong, John R. Mascola Immunity

Brief introduction to the immune system

Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

Christina Beatrice Karsten, Galit Alter Cell Reports

HIV Immunology Goes Out On a Limb

N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R

TB VACCINES WORKING GROUP

Reverse Vaccinology: Developing Vaccines in the Era of Genomics

Zika Virus: Immunity and Vaccine Development

Ricardo U. Sorensen, MD, Luke A. Wall, MD

Will There Be a Vaccine to Protect Against the Hepatitis C Virus?

N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R

Molecular virology and immunology of HIV infection

HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98%

Paradigm for the cycle of precision vaccinology.

Presentation transcript:

? Neutralizing Antibodies: Research pathways in 2013 and beyond HIV-infected individual Broadly neutralizing antibodies Reverse Engineering Vaccines Passive Immunization Trials A protein from HIV surface (envelope) interacting with an antibody. Molecular characterization of the interaction between HIV envelope and BNAbs * Modified env Development of immunogens to mimic the portion of HIV envelope that connects with BNAbs * Combination of several immunogens = vaccine Development of clinical grade purified form of BNAbs Phase I: Safety and pharmacokinetic evaluation Phase II/III: Efficacy trials ? Neutralizing Antibodies: Research pathways in 2013 and beyond Source: Adapted from: Burton, “Antibodies, viruses and vaccines,” Nature Reviews Immunology (2002) 2: 706-713.